Soleno Therapeutics, Inc.
↗Redwood City, California, USA
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Headquartered in Redwood City, California, the company was originally incorporated in 1999 as Capnia, Inc. and rebranded to Soleno Therapeutics in May 2017. The company's lead product, VYKAT XR (diazoxide choline extended-release tablets), was FDA-approved on March 26, 2025, for the treatment of hyperphagia in patients 4 years and older with Prader-Willi syndrome (PWS), representing the first FDA-approved therapy for this indication. With the commercial launch beginning April 2025, Soleno has rapidly achieved profitability, generating $66.0 million in Q3 2025 revenue with 764 active patients on therapy as of September 30, 2025.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$98.7M (9M 2025)
Founded:1999
Ownership:public
Status:operating
FUNDING
Stage:Commercial
Total Raised:$260M+
Investors:Oxford Finance LLC, Perceptive Advisors, Nantahala Capital Management, Abingworth LLP, Vivo Capital
STOCK
Exchange:NASDAQ
Ticker:SLNO
Market Cap:$2.56B
PIPELINE
Stage:Commercial
Lead Drug Stage:FDA Approved - Commercial
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 3: 1
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Capnia, Inc.
Key Partnerships:Oxford Finance LLC (debt financing partner - $200M facility), CoSense Monitoring Technology (joint venture), University of California, San Diego (research partnership for metabolic disorders)
COMPETITION
Position:First Mover
Competitors:H3 histamine receptor antagonists (WAKIX/pitolisant), Oxytocin receptor agonists (Carbetocin/ACP-101), TAS2R agonists (ARD-101), MCHR1 inhibitors (RGH-706), PDE-10 inhibitors (PBF-999)
LEADERSHIP
Key Executives:
Dr. Anish Bhatnagar - Chief Executive Officer and Chairman
Dr. Joshi - Chief Development Officer
Dr. Nagao - Senior Vice President of Medical Affairs
Yen - Senior Vice President of Global Clinical Operations and Patient Advocacy
Board Members:Dr. Anish Bhatnagar (CEO and Chairman), Matthew Pauls (Lead Independent Director), Dawn Carter Bir (Board Member), Mark W. Hahn (Independent Director, Audit Committee Member), Dr. Sinclair (Board Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Soleno Therapeutics, Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.